Abstracts tagged "Psoriatic arthritis"

Abstract Number: 0504 • ACR Convergence 2020
Efficacy and Safety of Upadacitinib in Patients with Active Psoriatic Arthritis and Inadequate Response to Biologic Disease-Modifying Anti-Rheumatic Drugs: A Double-Blind, Randomized Controlled Phase 3 Trial
Mark Genovese¹, Apinya Lertratanakul², Jaclyn K Anderson², Kim Papp³, William Tillett⁴, Filip Van den Bosch⁵, Shigeyoshi Tsuji⁶, Eva Dokoupilova⁷, Mauro Keiserman⁸, Xin Wang², Sheng Zhong², Patrick Zueger², Aileen Pangan⁹ and Philip Mease¹⁰, ¹Stanford University Medical Center, Palo Alto, CA, ²AbbVie Inc., North Chicago, IL, ³Papp Clinical Research and Probity Medical Research, Waterloo, ON, Canada, ⁴Royal National Hospital for Rheumatic Diseases, Bath, UK; Department of Pharmacy and Pharmacology, University of Bath, Bath, UK, Bath, United Kingdom, ⁵Ghent University Hospital, Ghent, Belgium, ⁶Department of Orthopaedics/Rheumatology, National Hospital Organization, Osaka Minami Medical Center, Osaka, Japan, ⁷Uherske Hradiste and University of Veterinary and Pharmaceutical Sciences,, Brno, Czech Republic, ⁸Pontificial Catholic University, Porto Alegre, Brazil, ⁹Abbvie Inc., La Grange, IL, ¹⁰Seattle Rheumatology Associates, P.L.L.C., Seattle, WA
Background/Purpose: Upadacitinib (UPA) is an oral, reversible, JAK inhibitor approved for treatment of moderate to severe rheumatoid arthritis (RA) and currently under evaluation for treatment…
Abstract Number: 0891 • ACR Convergence 2020
Four-Year Efficacy and Safety of Guselkumab in Psoriasis Patients with and Without Psoriatic Arthritis: A Pooled Analysis from VOYAGE 1 and VOYAGE 2
Kristian Reich¹, Jan Dutz², Peter Foley³, Diamant Thaçi⁴, Ron Vender⁵, Michael Song⁶, Megan Miller⁶, Yin Yu⁶, Shu Li⁷, Yaung-Kaung Shen⁶ and April W. Armstrong⁸, ¹Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, and Skinflammation®, Hamburg, Germany, ²Vancouver General Hospital, Vancouver, Canada, ³University of Melbourne, St. Vincent’s Hospital, Melbourne and Skin & Cancer Foundation Inc, Carlton, Australia, ⁴Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany, ⁵McMaster University, Hamilton, Canada, ⁶Janssen Research & Development, LLC, Spring House, ⁷Janssen Scientific Affairs, LLC, Horsham, ⁸Keck School of Medicine of University of Southern California, Los Angeles, CA
Background/Purpose: Guselkumab (GUS), a fully human monoclonal antibody, selectively binds and blocks IL-23. VOYAGE 1 and VOYAGE 2 are two ongoing Phase 3, randomized, double-blind,…
Abstract Number: 1030 • ACR Convergence 2020
Pain Medication Use Among Ankylosing Spondylitis and Psoriatic Arthritis Patients Before and After Initiation of Biologic Therapy
Theresa Hunter¹, Chi Nguyen², Julie Birt³, Joseph Smith², Mingyang Shan³, Hiangkiat Tan², Jeffrey Lisse³ and Keith Isenberg⁴, ¹Eli Lilly and Company, Indianapolis, ²Healthcore, Inc, Wilmington, DE, ³Eli Lilly and Company, Indianapolis, IN, ⁴Anthem, Inc, Indianapolis, IN
Background/Purpose: Pain is a common symptom among ankylosing spondylitis (AS) and psoriatic arthritis (PsA) patients and can be debilitating, making pain management an integral part…
Abstract Number: 1344 • ACR Convergence 2020
Guselkumab, an IL-23 Inhibitor That Specifically Binds to the IL23p19-Subunit, for Active Psoriatic Arthritis: One Year Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Patients Who Were Biologic-Naïve or TNFα Inhibitor-Experienced
Christopher Ritchlin¹, Philip Helliwell², Wolf-Henning Boehncke³, Elizabeth Hsia⁴, Alexa Kollmeier⁵, Ramanand Subramanian⁶, Xie Xu⁷, Shihong Sheng⁶, Yusang Jiang⁶, Bei Zhou⁶ and Atul Deodhar⁸, ¹Department of Medicine, University of Rochester Medical Center, Rochester, NY, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ³Geneva University Hospitals, Geneva, Switzerland, ⁴Janssen Research & Development, LLC and University of Pennsylvania Medical Center, Spring House, PA, ⁵Janssen Research & Development, LLC, La Jolla, CA, ⁶Janssen Research & Development, LLC, Spring House, PA, ⁷Janssen Research & Development, LLC, San Marcos, CA, ⁸Oregon Health & Science University, Portland, OR
Background/Purpose: Guselkumab (GUS), a monoclonal antibody that specifically binds to the p19-subunit of IL-23, is approved to treat psoriasis (PsO). At Week 24 of the…
Abstract Number: 1374 • ACR Convergence 2020
Secukinumab in the Treatment of Dactylitis in Patients with Psoriatic Arthritis: Post Hoc Analysis Results from a Randomized Phase 3 Trial
Bruce Kirkham¹, Peter Nash², Sandra Navarra³, Erhard Quebe-Fehling⁴, Corine Gaillez⁴, Carlos Sastre⁴ and Philip Mease⁵, ¹Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom, ²School of Medicine Griffith University, Brisbane, Queensland, Australia, ³University of Santo Tomas, Manila, Philippines, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵Seattle Rheumatology Associates, P.L.L.C., Seattle, WA
Background/Purpose: Dactylitis is a key and frequent clinical manifestation of psoriatic arthritis (PsA)1 associated with significant disease burden and impaired function.2–3 Randomized controlled trials designed…
Abstract Number: 1850 • ACR Convergence 2020
The Association Between Imaging Sub-phenotypes of Psoriatic Arthritis and Gene Expression Profiles
Lihi Eder¹, Lee Quan², Sara Rahmati³, Iris Eshed⁴, Proton Rahman⁵, Igor Jurisica⁶ and Vinod Chandran⁷, ¹Women’s College Research Institute, University of Toronto, Toronto, ON, Canada, ²University of Toronto, Toronto, Canada, ³University Health Network, Toronto, ON, Canada, ⁴Sheba Medical Center, Tel-Aviv, Israel, ⁵Memorial University of Newfoundland, Department of Medicine, St John's, Canada, ⁶Krembil RI, Toronto, Canada, ⁷Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Heterogeneity is a hallmark of psoriatic arthritis (PsA), which is reflected in diverse clinical, imaging and molecular features, various disease courses and treatment responses.…
Abstract Number: 0309 • ACR Convergence 2020
Diagnostic Delay in Psoriatic Arthritis: A Population Based Study
Paras Karmacharya¹, Kerry Wright², Sara J. Achenbach³, Delamo Bekele², Cynthia Crowson⁴, Alexis Ogdie⁵, Ali Duarte-Garcia², Floranne C. Ernste³, Megha M. Tollefson¹ and John Davis², ¹Mayo Clinic, Rochester MN, ROCHESTER, MN, ²Mayo Clinic, Rochester, MN, ³Mayo Clinic, Rochester, ⁴Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN, ⁵University of Pennsylvania, Philadelphia, PA
Background/Purpose: Early diagnosis of psoriatic arthritis (PsA) is important for improving long-term outcomes. Trends in diagnostic delay of PsA in the US and factors associated…
Abstract Number: 0325 • ACR Convergence 2020
The Impact of PsA Disease Control Status on Patient Treatment Satisfaction: Real-world Survey in US and Europe
Ana-Maria Orbai¹, Elizabeth Holdsworth², Thomas Baker³, Chloe Middleton-Dalby², May Shawi³, Nicola Booth², James Piercy² and Steven Peterson⁴, ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Adelphi Real World, Bollington, United Kingdom, ³Janssen Global Services, LLC, Raritan, NJ, ⁴Janssen Immunology Global Commercial Strategy Organization, Horsham, PA
Background/Purpose: Patient satisfaction associated with disease control status among PsA patients has not been extensively studied in a real-world setting. The objective of this study…
Abstract Number: 0343 • ACR Convergence 2020
Co-expression of DC-STAMP and CX3CR1: Biomarkers for Tissue Resident Osteoclasts in Psoriatic Arthritis
Maria de la Luz Garcia-Hernandez¹, Javier Rangel-Moreno², Ananta Paine³, Benjamin Korman³, Marc Nuzzo⁴, Lihi Eder⁵ and Christopher Ritchlin³, ¹University of Rochester, Rochester, NY, ²University of Rochester Medical Center, Rochester, NY, ³Department of Medicine, University of Rochester Medical Center, Rochester, NY, ⁴Department of Medicine, University of Rochester Medical Center, Rochester, ⁵Women’s College Research Institute, University of Toronto, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) patients often experience joint damage mediated by osteoclasts (OC). Although PsA pathogenesis is poorly understood, the production of the cytokines IL-17,…
Abstract Number: 0368 • ACR Convergence 2020
Comparable Impact and Burden of Disease of Psoriatic Arthritis Patients with Limited Joint Involvement vs. Those with More Extensive Joint Involvement: Interim Results from a Prospective, Multicenter, Real-World Study in Patients Treated with Apremilast
Tim Jansen¹, Arie van Vliet² and Marijn Vis³, ¹Viecuri MC, Venlo, Netherlands, ²Amgen B.V., Breda, Netherlands, ³Erasmus UMC, Rotterdam, Netherlands
Background/Purpose: Psoriatic arthritis (PsA) is associated with a high burden of disease and an increased risk of comorbidities. Recent data suggest that patients with moderate…
Abstract Number: 0505 • ACR Convergence 2020
Secukinumab Provides Sustained Improvements in Clinical and Imaging Outcomes in Patients with Psoriatic Arthritis and Axial Manifestations: Results from the MAXIMISE Trial
Xenofon Baraliakos¹, Laure Gossec², Effie Pournara³, Slawomir Jeka⁴, Ricardo Blanco⁵, Salvatore D'Angelo⁶, Georg Schett⁷, Barbara Schulz³, Michael Rissler³, Dermot Whyms⁸, Chiara Perella³ and Laura Coates⁹, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Bochum, Germany, ²Sorbonne Université and Hôpital Universitaire Pitié Salpêtrière, Paris, France, ³Novartis Pharma AG, Basel, Switzerland, ⁴2nd Univ Hospital, CM UMK, Bydgoszcz, Poland, ⁵Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain, ⁶Rheumatology Department of Lucania and Rheumatology Institute of Lucania (IRel), San Carlo Hospital of Potenza, Potenza, Italy, ⁷Friedrich-Alexander-Universität Erlangen- Nuremberg, Erlangen, Germany, ⁸Novartis Ireland Limited, Dublin, Ireland, ⁹University of Oxford, Oxford, United Kingdom
Background/Purpose: Axial disease may affect up to 25–70% of psoriatic arthritis (PsA) patients, depending on the definition used. Current evidence on efficacy of biologics in…
Abstract Number: 0894 • ACR Convergence 2020
Efficacy and Safety of Neihulizumab (AbGn-168H) in Patients with Active Psoriatic Arthritis: 24-week Results from a Phase II Open Label Study
Stanley Cohen¹, Justus Fiechtner², Philip Mease³, Jeffrey Kaine⁴, Arthur Kavanaugh⁵, Yi-Lin (Irene) Cheng⁶, Claire Chou⁶, Ting-Ying Cheng⁷, Shih-Yao Lin⁶ and Mark Genovese⁸, ¹University of Texas Southwestern Medical School at Dallas, and Metroplex Clinical Research Center, Dallas, TX, ²Michigan State University, Grand Rapids,, MI, ³Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ⁴Sarasota Arthritis Research Center, Sapphire, NC, ⁵UC San Diego Health System, San Diego, CA, ⁶AltruBio, Taipei, Taiwan (Republic of China), ⁷AltruBio, Redwood City, CA, ⁸Stanford University Medical Center, Palo Alto, CA
Background/Purpose: Neihulizumab is a novel immune checkpoint agonistic antibody that binds to human CD162 (PSGL-1), thereby preferentially inducing apoptosis in late stage activated T cells.…
Abstract Number: 1031 • ACR Convergence 2020
Real World Treatment Patterns Among Patients with Psoriatic Arthritis Treated with Ixekizumab
Mwangi Murage¹, Nicole Princic², Julie Park², William Malatestinic¹, Baojin Zhu¹, Bilal Atiya¹, Scott Kern¹, Keri Stenger¹, Aubrey Sprabery¹ and Alexis Ogdie³, ¹Eli Lilly and Company, Indianapolis, IN, ²IBM Watson Health, Cambridge, MA, ³University of Pennsylvania, Philadelphia, PA
Background/Purpose: Psoriatic arthritis (PsA) is a systemic condition estimated to affect 0.05%-0.25% of the United States (US)1 population. With approval of ixekizumab (a selectively binding…
Abstract Number: 1345 • ACR Convergence 2020
Upadacitinib as Monotherapy and in Combination with Non-biologic DMARDs for the Treatment of Psoriatic Arthritis: Subgroup Analysis from Two Phase 3 Trials
Peter Nash¹, Pascal Richette², Laure Gossec³, Antonio Marchesoni⁴, Koji Kato⁵, Erin Blondell⁶, Elizabeth Lesser⁶, Reva M McCaskill⁶, Dai Feng⁶, Jaclyn K Anderson⁶ and Eric Ruderman⁷, ¹School of Medicine Griffith University, Brisbane, Queensland, Australia, ²Department of Rheumatology, Lariboisière Hospital, Paris, France, ³Sorbonne Université and Hôpital Universitaire Pitié Salpêtrière, Paris, France, ⁴ASST Gaetano Pini-CTO, Milano, Italy, ⁵AbbVie Inc, North Chicago, IL, ⁶AbbVie Inc., North Chicago, IL, ⁷Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: Approximately 40% of PsA patients (pts) on advanced therapy are on monotherapy.1,2 Upadacitinib (UPA) has shown efficacy and safety in pts with active PsA…
Abstract Number: 1400 • ACR Convergence 2020
cAMP Response Element Modulator (CREM)α Promotes PD-1- effector CD4+ T Cells in Psoriasis and Psoriatic Arthritis
Sigrun Hofmann¹, Franz Kapplusch², Susanne Abraham³, Sarah Northey², Susanne Russ¹, Felix Schulze¹, Anna Surace⁴ and Christian Hedrich⁵, ¹Klinik und Poliklinik für Kinder- und Jugendmedizin, Universitätsklinikum Carl Gustav Carus, TU Dresden, Dresden, Germany., Dresden, Germany, ²Department of Women's and Children's Health, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom., Liverpool, United Kingdom, ³Klinik und Poliklinik für Dermatologie, Universitätsklinikum Carl Gustav Carus, TU Dresden, Dresden, Germany., Dresden, Germany, ⁴Centre for Experimental Medicine and Rheumatology, Queen Mary University of London, Liverpool, United Kingdom, ⁵University of Liverpool, Liverpool, United Kingdom
Background/Purpose: Psoriasis is a systemic autoimmune/inflammatory condition that primarily affects the skin, but also other organ systems. Effector CD4+ T lymphocytes have been identified as…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].